SCHEMBL427656

SCHEMBL427656

CC1(C)COCN1C(=O)n1cnc(-c2ccc(O)c(N)c2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP9 Q86TI2 1/20 0.33
CNR2 P34972 2/20 0.32
KDM4E B2RXH2 3/20 0.31
ALDH1A1 P00352 3/20 0.31
GAA P10253 3/20 0.31
HPGD P15428 3/20 0.31
HSD17B10 Q99714 3/20 0.31
CYP1A2 P05177 2/20 0.31
GLA P06280 1/20 0.31
CYP2C9 P11712 1/20 0.31
TSHR P16473 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
POLB P06746 1/20 0.31
CYP2C19 P33261 1/20 0.31
MEN1 O00255 1/20 0.30
USP2 O75604 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425981 0.87 MIF (0.36) CNR2KDM4EHSD17B10LMNA
SCHEMBL426001 0.87 CNR2 (0.37) DPP4DPP8DPP9CNR2ALDH1A1
SCHEMBL427535 0.85 CNR2 (0.35) DPP4DPP8DPP9CNR2KDM4E
SCHEMBL427043 0.85 FYN (0.39) GAA
SCHEMBL425883 0.85 KDM1A (0.33) DPP4DPP8DPP9CNR2KDM4E
SCHEMBL427643 0.85 HSD17B1 (0.37) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL426016 0.83 MAP4K4 (0.42) DPP4DPP8DPP9CNR2KDM4E
SCHEMBL427118 0.82 DPP4 (0.40) DPP4DPP8DPP9CNR2KDM4E
SCHEMBL425743 0.82 FAAH (0.43) DPP4DPP8DPP9CNR2KDM4E
SCHEMBL427620 0.81 KDM4E (0.38) CNR2KDM4EALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 DPP4 322/4885DPP8 551/4885DPP9 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.